AQST
Aquestive Therapeutics, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$5.34
−0.19%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−10.3x
Market Cap
$670.23M
MomentumView details →
1D Return
−0.19%
YTD Return
−16.29%
RSI (14)
71.1
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−10.3x
Market Cap
$670.23M
RSI (14)
71.1
MomentumView details →
1D Return
−0.19%
YTD Return
−16.29%
SummaryUpdated Jun 1, 2026
Aquestive Therapeutics, Inc. (NASDAQ:AQST) is a specialty pharmaceutical company founded in 2004 and headquartered in Warren, New Jersey. The company went public in July 2018 and focuses on developing and commercializing innovative drug delivery technologies, particularly through its proprietary oral soluble film platform. Aquestive has evolved from a contract manufacturing organization into a fully integrated pharmaceutical company with both commercial products and a robust pipeline of proprietary drug candidates targeting various therapeutic areas including epilepsy, anaphylaxis, ADHD, and rare diseases.
Similar companies
Latest newsMore news →
Aquestive Therapeutics reported its financial results for the second quarter ended June 30, 2026.24d agoAquestive Therapeutics announced positive topline results from human factors and pharmacokinetic studies for its Anaphylm (dibutepinephrine) sublingual film, supporting a planned NDA resubmission to the FDA in Q3 2026.26d ago